Abstract 3874: Genomic mechanisms of resistance to tyrosine kinase inhibitors (TKIs) in HER2+ metastatic breast cancer (HER2+ MBC)
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-3874
Abstract: Background. Despite substantial progress in the treatment of HER2+ MBC, most patients (pts) still experience disease progression and cancer-related death. HER2-directed TKIs are highly effective therapies for pts with HER2+ MBC; however, an understanding of… read more here.
Keywords: breast cancer; her2 mbc; resistance; cancer ... See more keywords
Abstract P3-11-01: Treatment patterns for young women with HR+/HER2- metastatic breast cancer in the United States in the era of CDK 4/6 inhibitors
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Research"
DOI: 10.1158/1538-7445.sabcs17-p3-11-01
Abstract: Background : NCCN guidelines recommend that premenopausal women with HR+/HER2- metastatic breast cancer (MBC) be rendered postmenopausal and then treated accordingly. After its approval in February 2015, the CDK4/6 inhibitor palbociclib (P), in combination with… read more here.
Keywords: her2 mbc; treatment; breast cancer; women her2 ... See more keywords
A randomized phase II trial of fulvestrant with or without ribociclib after progression on aromatase inhibition plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2017.35.15_suppl.tps1112
Abstract: TPS1112Background: CDK4/6i, including palbociclib and ribociclib (R), have demonstrated remarkable benefit in progression free survival (PFS) in patients (pts) with HR+, HER2- MBC with anti-estrogen therapy. Switching between anti-estrogen therapies at disease progression is standard… read more here.
Keywords: trial; fulvestrant; her2 mbc; inhibition ... See more keywords
Real-world outcomes among patients with HER2+ metastatic breast cancer with brain metastases.
Sign Up to like & getrecommendations! Published in 2022 at "Journal of managed care & specialty pharmacy"
DOI: 10.18553/jmcp.2022.28.6.657
Abstract: BACKGROUND: Among patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer (MBC), incidence of brain metastases (BMs) is relatively high and increasing. Despite the high unmet need for patients with HER2+ MBC… read more here.
Keywords: seagen inc; seagen; patients her2; among patients ... See more keywords
Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Management and Research"
DOI: 10.2147/cmar.s162714
Abstract: Background Hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−), metastatic breast cancer (MBC) accounts for 73% of all MBCs. Endocrine therapy (ET) is the basis of first-line (1L) therapy for patients with HR+/HER2−… read more here.
Keywords: pfs; line; her2 mbc; progression ... See more keywords
Oral Etoposide and Trastuzumab Use for HER2-Positive Metastatic Breast Cancer: A Retrospective Study from the Institut Curie Hospitals
Sign Up to like & getrecommendations! Published in 2022 at "Cancers"
DOI: 10.3390/cancers14092114
Abstract: Simple Summary Oral etoposide (VP16), an inhibitor of topoisomerase-II, has demonstrated clinical activity in metastatic breast cancer (MBC). To our knowledge, oral VP16 combined with trastuzumab (VP16-T) in HER2+ MBC has not been evaluated before.… read more here.
Keywords: breast; oral etoposide; her2 mbc; vp16 ... See more keywords